Group 1 - The A-share cosmetics sector experienced a significant rise in the afternoon, with Huaye Fragrance hitting the daily limit up [1] - Furuida, Lafang Home, and Bawi Co. previously reached their daily limit, while Qingsong Co. surged over 10% [1] - Other companies such as Shanghai Jahwa, Proya, Jiaheng Home, Jinsong New Materials, and Beitaini also saw increases [1]

证券代码：837023 证券简称：芭薇股份 公告编号：2025-040 广东芭薇生物科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、投资者关系活动类别 □特定对象调研 □现场参观 □新闻发布会 □路演活动 □其他 二、投资者关系活动情况 上市公司接待人员：公司董事长、总经理冷群英女士，董事会秘书单楠先生， 财务总监夏玲玲女士，万联证券保荐代表人钟建高先生。 三、投资者关系活动主要内容 √业绩说明会 □媒体采访 活动时间：2025 年 5 月 13 日 本次业绩说明会通过 PPT 解读的方式对公司 2024 年年度经营情况进行了简 单的介绍与总结。同时，公司在业绩说明会上跟投资者进行了互动交流，并就投 资者普遍关注的问题进行了回复，主要问题及回复如下： 活动地点：中证路演中心（https://www.cs.com.cn/roadshow/） □分析师会议 参会单位及人员：通过网络方式参加公司 2024 年年度报告业绩说明会的投 资者 回复：尊敬的投资者，您好！ ...

芭薇股份（837023）今日上涨5.48%，全天换手率38.43%，成交额3.22亿元，振幅16.55%。龙虎榜数据 显示，营业部席位合计净买入1051.15万元。 北交所公开信息显示，当日该股因日换手率达38.43%上榜，营业部席位合计净买入1051.15万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交5188.87万元，其中，买入成交额为 3120.01万元，卖出成交额为2068.86万元，合计净买入1051.15万元。 具体来看，第一大买入营业部及卖出营业部均为国信证券股份有限公司深圳红岭中路证券营业部，买入 金额为702.42万元，卖出金额为530.50万元。 近半年该股累计上榜龙虎榜10次，上榜次日股价平均跌1.50%，上榜后5日平均跌4.80%。（数据宝） 芭薇股份5月9日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 国信证券股份有限公司深圳红岭中路证券营业部 | 702.42 | 530.50 | | 买二 | 国金证券股份有限公司深圳湾一号证券营业部 | 493. ...

二、说明会召开的时间、地点 证券代码：837023 证券简称：芭薇股份 公告编号：2025-039 广东芭薇生物科技股份有限公司 2024 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、说明会类型 广东芭薇生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日 在北京证券交易所官方信息披露平台（http://www.bse.cn/）发布了《2024 年 年度报告》（公告编号：2025-012），为方便广大投资者更深入了解公司 2024 年 年度经营业绩的具体情况，加强与投资者的互动交流，公司拟召开 2024 年年度 报告业绩说明会。 为充分尊重投资者，提升交流的针对性，现就公司 2024 年年度报告业绩说 明会提前向投资者公开征集问题。投资者可于 2025 年 5 月 13 日 15:00 前访问 https://rs.cs.com.cn/dist/#/index?id=c53dc5ddfbf745f18a206bc91c1a4c14 或扫描下方二 ...

Investment Rating - The report maintains an "Outperform" rating for the North Exchange market [5] Core Insights - The North Exchange has entered the "920 era," marking the emergence of the first ST companies [1] - The North Exchange's total number of listed companies is 265, with a total market capitalization of 737.724 billion and a circulating market capitalization of 441.839 billion, reflecting a quarter-on-quarter increase of 5.2% and 4.3% respectively [1][11] - The North Exchange 50 Index experienced a significant rebound, ending the month with a 4.72% increase, while other major indices declined [2][30] - The report highlights that 16 out of 22 industries on the North Exchange saw gains, with notable increases in beauty care, transportation, food and beverage, textiles, and agriculture, with median increases exceeding 15% [2][35] Market Overview - The North Exchange's trading volume for April was 30.945 billion shares, with a total transaction value of 630.962 billion, representing a quarter-on-quarter decrease of 14.4% and 20.2% respectively [1][17] - The average daily margin balance for April reached 5.262 billion, remaining at a historically high level [22] - As of April 30, the North Exchange 50 Index's price-to-earnings ratio (PE-TTM) was 45.31, placing it in the 99.79th percentile over the past two years [24][27] Industry Performance - The highest median price-to-earnings ratios by industry were recorded in the computer sector at 111, followed by telecommunications at 110, construction materials at 91, light industry manufacturing at 74, and social services at 72 [24][27] - The report indicates that 23 stocks reached historical highs in price during the month, with Huaguang Yuanhai achieving a remarkable 65.42% increase [2][39] Company Announcements - In April 2025, 232 companies on the North Exchange released their annual reports, with Jinbo Biological reporting the highest earnings per share at 8.27 yuan [3][12] - The report notes that there were no new listings in April, but one new stock, Tiangong Co., was issued [3][11] Policy and Important Events - The North Exchange introduced several policies in April 2025 related to refinancing, trading management, broker performance evaluation, and delisting supervision, marking a strategic move towards market independence and specialization [3][14]

具体来看，今日上榜营业部中，第一大买入营业部为国信证券股份有限公司深圳红岭中路证券营业部， 买入金额为633.49万元，第一大卖出营业部为东北证券股份有限公司黑龙江分公司，卖出金额为559.90 万元。 芭薇股份（837023）今日下跌2.02%，全天换手率25.76%，成交额2.04亿元，振幅7.40%。龙虎榜数据显 示，营业部席位合计净买入304.18万元。 北交所公开信息显示，当日该股因日换手率达25.76%上榜，营业部席位合计净买入304.18万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4826.58万元，其中，买入成交额为 2565.38万元，卖出成交额为2261.20万元，合计净买入304.18万元。 近半年该股累计上榜龙虎榜10次，上榜次日股价平均跌3.12%，上榜后5日平均跌8.28%。（数据宝） 芭薇股份4月30日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 国信证券股份有限公司深圳红岭中路证券营业部 | 633.49 | 65.94 | | 买二 | 国泰海 ...

美容护理板块午后持续拉升，芭薇股份涨超15%，丸美生物（603983）此前涨停，上海家化 （600315）、百亚股份（003006）跟涨。 ...

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company achieved a revenue of 695 million yuan in 2024, representing a year-on-year growth of 48.3%, and a net profit of 45 million yuan, up 10.3% year-on-year, which met expectations [7] - The company plans to distribute a cash dividend of 3.0 yuan per share (including tax) for 2024, with a distribution ratio of 56.71% [7] - In Q1 2025, the company reported a revenue of 162 million yuan, a year-on-year increase of 40.1%, and a net profit of 9 million yuan, up 8.8% year-on-year, slightly below expectations [7] - The company is focusing on a major client strategy and has formed partnerships with emerging brands to drive revenue growth, with domestic revenue reaching 642 million yuan in 2024, a 40.5% increase [7] - The company is enhancing its raw material research and investment to improve integrated capabilities and increase the value-added of its OEM services [7] - The profit forecast for 2025-2027 has been adjusted downwards, with expected net profits of 69 million yuan, 91 million yuan, and 115 million yuan respectively [7] Financial Data and Profit Forecast - Total revenue is projected to reach 1,009 million yuan in 2025, with a year-on-year growth rate of 45.2% [6] - The gross profit margin is expected to be 26.4% in 2025, with a net profit margin of 6.5% [6] - The company’s return on equity (ROE) is forecasted to be 15.6% in 2025 [6] - The earnings per share (EPS) is projected to be 0.81 yuan in 2025 [6]

Core Viewpoint - The "climax needle" concept has led to significant stock price fluctuations in related companies, highlighting the volatility and speculative nature of the medical beauty industry [1][4]. Group 1: Market Reaction - On April 28, after the opening of A-shares, stocks related to the "climax needle" concept experienced a collective decline, with Bawei Co. (837023) dropping over 9%, Demei Chemical (002054.SZ) down more than 7%, and Tianyuan Co. (002386.SZ) falling over 5% [1]. - Prior to the decline, these stocks had surged due to speculation surrounding the "climax needle," with some reaching their daily limit [1]. Group 2: Product Details - The "climax needle" is marketed as an injection of collagen at sensitive points within the female vagina, with prices ranging from thousands to tens of thousands of yuan [1]. - A specific product developed by Yuanxiang Biotechnology is priced at 9,800 yuan per injection and is classified as a "platelet-rich plasma preparation device" (PRP), which is a strictly regulated Class III medical device [3]. Group 3: Medical and Regulatory Insights - PRP technology involves extracting a patient's blood, processing it to concentrate platelets, and utilizing growth factors for tissue repair and regeneration [3]. - While PRP has been increasingly applied in the medical beauty sector, the National Medical Products Administration has not yet issued clear approvals for its use in facial injections, despite existing clinical literature [3][4]. - Experts have criticized the "climax needle" as lacking scientific support and warned of potential risks associated with its use, indicating a need for regulatory scrutiny in the medical beauty industry [1][4].

证券代码：837023 证券简称：芭薇股份 公告编号：2025-038 广东芭薇生物科技股份有限公司 持股 5%以上股东减持股份结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、减持主体减持前基本情况 | 股东名称 | 股东身份 | | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 广州云美产业投资合 | 持 股 | 5% 以 | 7,142,857 | 8.33% | 北京证券交易所上市 | | 伙企业（有限合伙） | 上股东 | | | | 前取得 | 二、减持计划的实施结果 三、备查文件目录 | | | | | | 减持价格区 | | 减 | 当前持股 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 间 | | 持 | 数量（股） | | | | | 已减 | 减 | | | | 计 | | ...